Claudio Contreras, MD
Ophthalmology · San Jose, CANPI 1184663387
Payments from drug & device makers
Across 10 payments — averaging $213.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$250
- Genentech USA, Inc.$149
- Oyster Point Pharma, Inc.$132
- Bausch & Lomb Americas Inc.$123
- Novartis$22
- plus $34 from 2 others
What the payments were for
- Travel & lodging$1,10552%
- Food & beverage$1,03048%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 2 | $1,425 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $250 |
| Genentech USA, Inc. | 1 | $149 |
| Oyster Point Pharma, Inc. | 2 | $132 |
| Bausch & Lomb Americas Inc. | 1 | $123 |
| Novartis | 1 | $22 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,425
- Tecnis 3-piece IOL$1,425
- Tecnis Symphony IOL$1,425
- Tecnis Symphony Toric IOL$1,425
- VYZULTA$250
- MIEBO$123
How this compares
$2,135 in reported general payments places this provider in the 55th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 164 | $111,897 |
| Restasis MultidoseCyclosporine | 108 | $67,069 |
| RestasisCyclosporine | 109 | $65,870 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 163 | $46,564 |
| XdemvyLotilaner | 13 | $24,356 |
| RocklatanNetarsudil Mesylat/Latanoprost | 39 | $19,860 |
| VyzultaLatanoprostene Bunod | 54 | $16,024 |
| TyrvayaVarenicline Tartrate | 18 | $10,000 |
| MieboPerfluorohexyloctane/Pf | 12 | $8,725 |
| Prednisolone Acetate | 322 | $7,962 |
| Cyclosporine | 31 | $7,429 |
| LumiganBimatoprost | 19 | $6,889 |
| Latanoprost | 574 | $5,998 |
| MoxifloxacinMoxifloxacin Hcl | 253 | $5,046 |
| Travoprost | 41 | $4,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $123 | $136,646230 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $21 | $24,35613 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $132 | $10,00018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Jose
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.